ArticleThe Lancet regional health. Western Pacific2026
Trends and disparities in hepatitis B burden in the Western Pacific Region, 2015-2024: a subregional analysis using modelled data.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Western Pacific Region (WPR) carries one of the world's largest hepatitis B virus (HBV) burdens, but elimination progress remains uneven. We assessed changes in HBV burden and heterogeneity in elimination progress across the WPR during 2015-2024. Methods: We conducted a regional ecological study using standardised modelled estimates from the Center for Disease Analysis Foundation for 34 WPR countries and areas from 2015 to 2024. Country-specific temporal trends were quantified using log-linear regression to estimated annual percentage change (EAPC) with 95% CIs. We assessed incidence-mortality divergence, differences in EAPCs across analytical subregions, associations between vaccination coverage and HBV burden, and sensitivity to influential observations, shared model trajectories, non-linearity, and alternative country classification. Findings: Regional HBV prevalence declined from 5.28% (95% UI 4.23-6.34) in 2015 to 4.58% (3.66-5.49) in 2024, and chronic HBV incidence declined from 6.32 to 3.16 per 100,000 population. Under-five prevalence plateaued at approximately 0.28-0.29% from 2019, remaining above the WHO 2030 target of ≤0.1%. Crude modelled HBV mortality increased from 22.88 to 24.70 per 100,000. Of 34 countries and areas, 55.9% had declining chronic incidence alongside increasing mortality. Incidence and mortality EAPCs were modestly correlated (r = 0.39, 95% CI 0.06-0.64; p = 0.023), while evidence of systematic differences across analytical subregions was limited. Interpretation: Declining HBV incidence has not been accompanied by declining mortality in many WPR countries and areas. Elimination monitoring should therefore assess transmission and mortality as distinct outcomes and account for substantial country-level heterogeneity. Funding: World Health Organization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.